CGTX - Cognition Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.31 0.1 (7.63%) --- 0.0 (0.3%) 0.0 (0.36%) 0.03 (2.29%) 0.05 (4.06%) 0.0 (0.0%) -0.03 (-2.19%)

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.11
Diluted EPS:
-0.11
Basic P/E:
-12.8182
Diluted P/E:
-12.8182
RSI(14) 1m:
68.66
VWAP:
1.41
RVol:

Events

Period Kind Movement Occurred At

Related News